




EMLc

ATC codes: **N03AD01**

Indication	Absence seizures, typical <span style="background-color: #008080; color: white; padding: 2px;">ICD11 code: 8A68.2</span>
INN	Ethosuximide
Medicine type	Device
List type	Complementary (EML) (EMLc)
Formulations	Oral > Liquid: 250 mg per 5 mL Oral > Solid: 250 mg
EML status history	First added in 1977 ( <a href="#">TRS 615</a> ) Changed in 1979 ( <a href="#">TRS 641</a> ) Changed in 1987 ( <a href="#">TRS 770</a> ) Changed in 2003 ( <a href="#">TRS 920</a> ) Changed in 2007 ( <a href="#">TRS 950</a> )
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 
Wikipedia	<a href="#">Ethosuximide</a> 
DrugBank	<a href="#">Ethosuximide</a> 

## Summary of evidence and Expert Committee recommendations

The EMLc Subcommittee endorsed the inclusion of ethosuximide on the complementary list of the EMLc for treatment of absence seizures in children.

